Science & Technology
IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43HL170910-01
Award Ceiling
$245K
Award Floor
$245K
Close Date
Jul 31, 2024
Total Funding
$245K
Expected Awards
1
Posted Date
Aug 18, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-1R43HL170910-01
Description
SBIR Phase Phase I award: "IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)" awarded to TARGETSITE THERAPEUTICS CORPORATION in New Haven, Connecticut. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $245,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.